Arvinas (ARVN) Change in Receivables (2017 - 2026)
Arvinas (ARVN) recorded quarterly Change in Receivables of -$800000.0 in Q1 2026, up 75.0% quarter-over-quarter from -$3.2 million in Q4 2025.
Arvinas (ARVN) Change in Receivables (2017 - 2026) Analysis & Trends
Arvinas' Change in Receivables history runs 10 years deep, the most recent figure standing at -$800000.0 for Q1 2026.
- In Q1 2026, Change in Receivables changed N/A year-over-year to -$800000.0; the TTM figure through Mar 2026 stood at -$5.5 million (down 711.11% YoY), while the FY2025 annual figure was -$4.7 million, down 687.5% from the prior year.
- Change in Receivables was -$800000.0 for Q1 2026 at Arvinas, up from -$3.2 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $17.1 million in Q3 2023 to a low of -$15.7 million in Q4 2023.
- Historically, Change in Receivables has averaged -$587500.0 across 5 years, with a median of -$450000.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables sank 1328.57% in 2022, then surged 3000.0% in 2024.
- A 5-year view of Change in Receivables shows it stood at $10.3 million in 2022, then plunged by 252.43% to -$15.7 million in 2023, then jumped by 103.18% to $500000.0 in 2024, then tumbled by 740.0% to -$3.2 million in 2025, then surged by 75.0% to -$800000.0 in 2026.
- The last three Change in Receivables figures came in at -$800000.0 (Q1 2026), -$3.2 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -800,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -800,000.00 |
| Mar 31, 2026 | -800,000.00 |
| Dec 31, 2025 | -3.20 Mn |
| Dec 31, 2025 | -3.20 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | -5.20 Mn |
| Jun 30, 2025 | -5.20 Mn |
| Dec 31, 2024 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | -2.50 Mn |
| Sep 30, 2024 | -2.50 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | -100,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Dec 31, 2023 | -15.70 Mn |
| Dec 31, 2023 | -15.70 Mn |
| Sep 30, 2023 | 17.10 Mn |
| Sep 30, 2023 | 17.10 Mn |